ImmuCell Corporation (ICCC)
ICCC Stock Price Chart
Explore ImmuCell Corporation interactive price chart. Choose custom timeframes to analyze ICCC price movements and trends.
ICCC Company Profile
Discover essential business fundamentals and corporate details for ImmuCell Corporation (ICCC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 May 1987
Employees
69.00
Website
https://immucell.comCEO
F. Olivier Te Boekhorst
Description
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
ICCC Financial Timeline
Browse a chronological timeline of ImmuCell Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is $0.05, while revenue estimate is $5.40m.
Earnings released on 14 May 2026
EPS came in at $0.21 surpassing the estimated $0.05 by +320.00%, while revenue for the quarter reached $10.36m , beating expectations by +91.77%.
Earnings released on 4 Mar 2026
EPS came in at -$0.31 falling short of the estimated -$0.01 by -3.00k%, while revenue for the quarter reached $7.63m , beating expectations by +41.22%.
Earnings released on 13 Nov 2025
EPS came in at -$0.02 , while revenue for the quarter reached $5.51m .
Earnings released on 14 Aug 2025
EPS came in at $0.06 , while revenue for the quarter reached $6.44m .
Earnings released on 14 May 2025
EPS came in at $0.16 , while revenue for the quarter reached $8.07m .
Earnings released on 25 Feb 2025
EPS came in at $0.06 , while revenue for the quarter reached $7.75m .
Earnings released on 13 Nov 2024
EPS came in at -$0.09 , while revenue for the quarter reached $6.01m .
Earnings released on 13 Aug 2024
EPS came in at -$0.20 , while revenue for the quarter reached $5.47m , beating expectations by +1.35%.
Earnings released on 14 May 2024
EPS came in at -$0.06 , while revenue for the quarter reached $7.26m , beating expectations by +34.40%.
Earnings released on 27 Feb 2024
EPS came in at -$0.15 , while revenue for the quarter reached $5.10m , missing expectations by -5.63%.
Earnings released on 13 Nov 2023
EPS came in at -$0.12 , while revenue for the quarter reached $5.40m , missing expectations by -0.06%.
Earnings released on 10 Aug 2023
EPS came in at -$0.18 , while revenue for the quarter reached $3.53m , missing expectations by -34.58%.
Earnings released on 11 May 2023
EPS came in at -$0.30 , while revenue for the quarter reached $3.45m , missing expectations by -36.18%.
Earnings released on 21 Feb 2023
EPS came in at -$0.22 , while revenue for the quarter reached $3.91m , missing expectations by -27.58%.
Earnings released on 21 Nov 2022
EPS came in at -$0.08 , while revenue for the quarter reached $4.80m , missing expectations by -11.19%.
Earnings released on 11 Aug 2022
EPS came in at -$0.09 , while revenue for the quarter reached $3.86m , missing expectations by -28.49%.
Earnings released on 12 May 2022
EPS came in at $0.09 surpassing the estimated -$0.10 by +190.00%, while revenue for the quarter reached $6.00m , beating expectations by +11.11%.
Earnings released on 22 Feb 2022
EPS came in at $0.01 surpassing the estimated -$0.01 by +200.00%, while revenue for the quarter reached $5.44m , beating expectations by +0.81%.
Earnings released on 15 Nov 2021
EPS came in at $0.02 surpassing the estimated -$0.06 by +133.33%, while revenue for the quarter reached $5.15m , beating expectations by +43.30%.
Earnings released on 12 Aug 2021
EPS came in at $0.02 surpassing the estimated -$0.08 by +125.00%, while revenue for the quarter reached $4.54m , beating expectations by +39.19%.
ICCC Stock Performance
Access detailed ICCC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
